# Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer

> **NCT00022217** · PHASE2 · UNKNOWN · sponsor: **Matrix Pharmaceutical**

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** carboplatin
- **DRUG:** cisplatin-e therapeutic implant
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00022217
- **Lead sponsor:** Matrix Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2000-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00022217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00022217, "Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00022217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*